Journal
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 11, Issue 2, Pages 531-533Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/21645515.2014.988553
Keywords
CDC-9; heterotypic protection; IRV; IgG-avidity; rotavirus
Categories
Ask authors/readers for more resources
To improve lower efficacy among infants in low income countries and the safety (e.g., rare but severe intussusception) of live oral rotavirus vaccines, we have developed CDC-9 strain with G1P[8] specificity as a candidate inactivated rotavirus vaccine (IRV). This IRV of 3 doses elicits high titers of IgG, neutralizing activity to homotypic and heterotypic human strains and IgG avidity in guinea pigs, thus is a promising alternative to enhance global immunization against rotavirus in children.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available